Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.0 - $21.0 $0 - $791,658
-37,698 Closed
0 $0
Q4 2022

Feb 14, 2023

BUY
$3.73 - $5.2 $61,545 - $85,800
16,500 Added 77.84%
37,698 $154,000
Q2 2021

Aug 16, 2021

SELL
$6.78 - $9.04 $606,043 - $808,058
-89,387 Reduced 80.83%
21,198 $167,000
Q1 2021

May 17, 2021

BUY
$8.18 - $23.98 $43,190 - $126,614
5,280 Added 5.01%
110,585 $933,000
Q4 2020

Feb 16, 2021

BUY
$15.81 - $29.0 $652,826 - $1.2 Million
41,292 Added 64.51%
105,305 $2.32 Million
Q3 2020

Nov 10, 2020

BUY
$18.75 - $28.58 $144,581 - $220,380
7,711 Added 13.7%
64,013 $1.3 Million
Q2 2020

Aug 14, 2020

BUY
$15.6 - $54.87 $878,311 - $3.09 Million
56,302 New
56,302 $1.56 Million

Others Institutions Holding IMRA

About IMARA Inc.


  • Ticker IMRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,287,300
  • Market Cap $552M
  • Description
  • IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develop...
More about IMRA
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.